Jan Piasecki

Jan Piasecki

Auto-generated profile, based on publicly available information

Jan Piasecki

Department of Philosophy and Bioethics, Faculty of Health Sciences, Jagiellonian University Medical College, Krakow, Poland

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 December 2017 in Science and Engineering Ethics
Verified
Journal Article
Open access
PDF file
JPJan Piasecki
Jan Piasecki
MWMarcin Waligora
Marcin Waligora
VDVilius Dranseika
Vilius Dranseika

29 October 2022 in BMC Medical Ethics
Verified
Journal Article
Open access
PDF file
JPJan Piasecki
Jan Piasecki
PCPhaik Yeong Cheah
Phaik Yeong Cheah
Background: The ownership status of individual-level health data affects the manner in which it is used. In this paper we analyze two competing models of the ownership status of the data discussed in the literature recently: private ownership and public ownership. Main body: In this paper we describe the limitations of these two models of data ownership with respect to individual-level health data, in particular in terms of ethical principles of justice and autonomy, risk mitigation, as well as technological, economic, and conceptual issues. We argue that undifferentiated application of neither private ownership nor public ownership will allow us to resolve all the problems associated with effective, equitable, and ethical use of data. We suggest that, instead of focusing on data ownership, we should focus on the institutional and procedural aspects of data governance, such as using Data Access Committees (DACs) or equivalent managed access processes, which can balance the elements of these two ownership frameworks. Conclusion: Undifferentiated application of the ownership concept (private or public) is not helpful in resolving problems associated with sharing individual-level health data. DACs or equivalent managed access processes should be an integral part of data governance. They can approve or disapprove data access requests after considering the potential benefits and harms to data subjects, their communities, primary researchers, and the wider society.

13 June 2014 in BMC Medical Ethics
Verified
Journal Article
Open access
PDF file
MWMarcin Waligora
Marcin Waligora
VDVilius Dranseika
Vilius Dranseika
JPJan Piasecki
Jan Piasecki
Assent is an important ethical and legal requirement of paediatric research. Unfortunately, there are significant differences between the guidelines on the details of assent.

3 February 2020 in BMC Medical Ethics
Verified
Journal Article
Open access
PDF file
Phaik Yeong CheahPhaik Yeong Cheah
Phaik Yeong Cheah
JPJan Piasecki
Jan Piasecki
Background: Sharing de-identified individual-level health research data is widely promoted and has many potential benefits. However there are also some potential harms, such as misuse of data and breach of participant confidentiality. One way to promote the benefits of sharing while ameliorating its potential harms is through the adoption of a managed access approach where data requests are channeled through a Data Access Committee (DAC), rather than making data openly available without restrictions. A DAC, whether a formal or informal group of individuals, has the responsibility of reviewing and assessing data access requests. Many individual groups, consortiums, institutional and independent DACs have been established but there is currently no widely accepted framework for their organization and function.Main text: We propose that DACs, should have the role of both promotion of data sharing and protection of data subjects, their communities, data producers, their institutions and the scientific enterprise. We suggest that data access should be granted by DACs as long as the data reuse has potential social value and provided there is low risk of foreseeable harms. To promote data sharing and to motivate data producers, DACs should encourage secondary uses that are consistent with the interests of data producers and their own institutions. Given the suggested roles of DACs, there should be transparent, simple and clear application procedures for data access. The approach to review of applications should be proportionate to the potential risks involved. DACs should be established within institutional and legal frameworks with clear lines of accountability, terms of reference and membership. We suggest that DACs should not be modelled after research ethics committees (RECs) because their functions and goals of review are different from those of RECs. DAC reviews should be guided by the principles of public health ethics instead of research ethics.Conclusions: In this paper we have suggested a framework under which DACs should operate, how they should be organised, and how to constitute them.

20 February 2018 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
MWMarcin Waligora
Marcin Waligora
MBMałgorzata M. Bała
Małgorzata M. Bała
MKMagdalena Koperny
Magdalena Koperny
MWMateusz T Wasylewski
Mateusz T Wasylewski
KSKarolina Strzebonska
Karolina Strzebonska
JKJonathan Kimmelman
Jonathan Kimmelman
Pediatric Phase I cancer trials are critical for establishing the safety and dosing of anti-cancer treatments in children. Their implementation, however, must contend with the rarity of many pediatric cancers and limits on allowable risk in minors. The aim of this study is to describe the risk and benefit for pediatric cancer Phase I trials. Our protocol was prospectively registered in PROSPERO (CRD42015015961). We systematically searched Embase and PubMed for solid and hematological malignancy Phase I pediatric trials published between 1 January 2004 and 1 March 2015. We included pediatric cancer Phase I studies, defined as “small sample size, non‑randomized, dose escalation studies that defined the recommended dose for subsequent study of a new drug in each schedule tested.” We measured risk using grade 3, 4, and 5 (fatal) drug-related adverse events (AEs) and benefit using objective response rates. When possible, data were meta-analyzed. We identified 170 studies meeting our eligibility criteria, accounting for 4,604 patients. The pooled overall objective response rate was 10.29% (95% CI 8.33% to 12.25%), and was lower in solid tumors, 3.17% (95% CI 2.62% to 3.72%), compared with hematological malignancies, 27.90% (95% CI 20.53% to 35.27%); p < 0.001. The overall fatal (grade 5) AE rate was 2.09% (95% CI 1.45% to 2.72%). Across the 4,604 evaluated patients, there were 4,675 grade 3 and 4 drug-related AEs, with an average grade 3/4 AE rate per person equal to 1.32. Our study had the following limitations: trials included in our review were heterogeneous (to minimize heterogeneity, we separated types of therapy and cancer types), and we relied on published data only and encountered challenges with the quality of reporting. Our meta-analysis suggests that, on the whole, AE and response rates in pediatric Phase I trials are similar to those in adult Phase I trials. Our findings provide an empirical basis for the refinement and review of pediatric Phase I trials, and for communication about their risk and benefit.

5 January 2023 in Frontiers in Psychiatry
Verified
Journal Article
Open access
PGPaweł Gwiaździński
Paweł Gwiaździński
AGAleksander B. Gundersen
Aleksander B. Gundersen
MPMichal Piksa
Michal Piksa
IKIzabela Krysińska
Izabela Krysińska
JKJonas R. Kunst
Jonas R. Kunst
JPJan Piasecki
Jan Piasecki
Introduction: The rise of social media users and the explosive growth in misinformation shared across social media platforms have become a serious threat to democratic discourse and public health. The mentioned implications have increased the demand for misinformation detection and intervention. To contribute to this challenge, we are presenting a systematic scoping review of psychological interventions countering misinformation in social media. The review was conducted to (i) identify and map evidence on psychological interventions countering misinformation, (ii) compare the viability of the interventions on social media, and (iii) provide guidelines for the development of effective interventions.Methods: A systematic search in three bibliographic databases (PubMed, Embase, and Scopus) and additional searches in Google Scholar and reference lists were conducted.Results: 3,561 records were identified, 75 of which met the eligibility criteria for the inclusion in the final review. The psychological interventions identified during the review can be classified into three categories distinguished by Kozyreva et al.: Boosting, Technocognition, and Nudging, and then into 15 types within these. Most of the studied interventions were not implemented and tested in a real social media environment but under strictly controlled settings or online crowdsourcing platforms. The presented feasibility assessment of implementation insights expressed qualitatively and with numerical scoring could guide the development of future interventions that can be successfully implemented on social media platforms.Discussion: The review provides the basis for further research on psychological interventions counteracting misinformation. Future research on interventions should aim to combine effective Technocognition and Nudging in the user experience of online services.Systematic review registration: [https://figshare.com/], identifier [https://doi.org/10.6084/m9.figshare.14649432.v2].